Find a Clinical Trial

Showing 1 - 10 of 290 Trials

A randomized controlled double-blind comparison of placebo, pulsed-electromagnetic field device, and pectoral block in mastectomy and reconstruction patients

Principal Investigator:

Christine H. Rohde, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT03360214

Population:

Adult

Phase:

IV

Pain after surgery is common, and it not only affects the post-operative patient experience but is also associated with development of chronic pain and delayed wound healing. Narcotic pain medications are usually prescribed after surgery, but they have many side effects. There are two types of non-narcotic pain control techniques currently in use at Columbia University Irving Medical Center (CUIMC). The first mode uses pulsed electromagnetic fields (PEMF). It is a painless device placed over dressings around the surgical site. The second type of technique uses a numbing medication called...
A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery

Principal Investigator:

Eileen Patricia Connolly, MD

Contact Number:

212-342-5162

NCT Number:

NCT01570998

Population:

Adult

Phase:

IV

The purpose of this study is to evaluate the use of targeted intraoperative radiation therapy (IORT), where radiation is given one time during surgery. This study is being done to see if there are any differences between women who receive standard radiation after surgery versus those who have IORT. IORT is given during surgery after the tumor has been removed. The IORT device, called Intrabeam Device®, is FDA approved to be used in all parts of the body to deliver radiation. It can deliver radiation therapy accurately targeted to the area of the breast where the tumor has been removed...
Head Start 4: Newly Diagnosed Children (Less Than 10 Years Old) With Medulloblastoma and Other Central Nervous System Primitive Neuro-Ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed By

Principal Investigator:

James Hinkley Garvin Jr, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT02875314

Population:

Pediatrics

Phase:

IV

This is a prospective randomized clinical trial, to determine whether dose- intensive tandem Consolidation, in a randomized comparison with single cycle Consolidation, provides an event-free survival (EFS) and overall survival (OS). The study population will be high-risk patients (non-Wnt and non-Shh sub-groups) with medulloblastoma, and for all patients with central nervous system (CNS) embryonal tumors completing Head Start 4 Induction. This study will further determine whether the additional labor intensity (duration of hospitalizations and short-term and long-term morbidities) associated...
A randomized phase III trial evaluating the role of axillary lymph node dissection in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Principal Investigator:

Bret Taback, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT01901094

Population:

Adult

Phase:

III

Patients with your type of breast cancer usually have neoadjuvant (which means “given before surgery) chemotherapy followed by breast and arm pit surgery to remove any remaining breast cancer. The lymph nodes in the arm pit are examined during surgery and if there is still cancer in the lymph nodes, then the majority of lymph nodes in the arm pit are removed. The purpose of this study is to examine whether removing some of the lymph nodes from the arm pit, but not removing them all followed with radiation therapy (experimental) will be as good as having the majority of the lymph nodes...
ANBL1232: Utilizing Response and Biology Risk Factors to guide Therapy in Patients with Non-Risks Neuroblastoma

Principal Investigator:

Justine Kahn, MD

Contact Number:

212-342-5162

NCT Number:

NCT02176967

Population:

Pediatrics

Phase:

III

This phase III study is looking at whether using certain risk factors and biomarkers (proteins and/or gene changes in tumor cells) to determine how much treatment a younger patient with non-high risk neuroblastoma should receive will allow for a decrease in treatment for these patients while still curing their neuroblastoma. For some patients, this may include no treatment and only close observation. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. This may help to avoid some of the risks and side effects related to...
AGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Principal Investigator:

Justine Kahn, MD

Contact Number:

212-342-5162

NCT Number:

NCT03067181

Population:

Pediatrics/Adult

Phase:

III

This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Are you Eligible? (Inclusion Criteria)...
An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Principal Investigator:

Nicole Lamanna, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT03336333

Population:

Adult

Phase:

III

The purpose of this study is to compare the effects, good or bad, of the experimental drug BGB-3111, versus a known standard treatment called bendamustine plus rituximab (B+R) on you and your chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to find out which is better. In this study you will receive either BGB-3111 or the standard chemotherapy treatment bendamustine plus rituximab (B+R). Are you Eligible? (Inclusion Criteria) To be eligible for this trial, participants must: Do you have a diagnosis of CLL or SLL? Are you at least 18 years old? Do you have adequate organ...
ACCL1633 - The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)

Principal Investigator:

Justine Kahn, MD

Contact Number:

212-342-5162

NCT Number:

NCT03057054

Population:

Pediatrics/Adult

Phase:

III

This randomized clinical trial is examining how well Lactobacillus plantarum works in preventing acute graft versus host disease in children who are undergoing stem cell transplant. Lactobacillus plantarum may help prevent the development of gastrointestinal graft versus host disease in children, adolescents, and young adults undergoing donor stem cell transplant. Are you Eligible? (Inclusion Criteria) Between 2 and 25 years of age Receiving an stem cell transplant from a donor No previous history of stem cell transplant or cellular therapy Patients must also meet all other eligibility...
AALL1631: International Phase 3 trial in Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) testing Imatinib in combination with two different cytotoxic chemotherapy backbones

Principal Investigator:

Justine Kahn, MD

Contact Number:

212-342-5162

NCT Number:

NCT03007147

Population:

Pediatrics/Adult

Phase:

III

This phase 3 study is examining the best treatments for Philadelphia chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). The goal of this study is to see if using a less toxic chemotherapy regimen in combination with Imatinib can effectively treat standard risk Ph+ ALL. Patients with high risk Ph+ ALL will receive more intensive chemotherapy followed by stem cell transplant. Are you Eligible? (Inclusion Criteria) must be at least greater than 1 year and less than 21 years of age Patients must be newly diagnosed Patients must also meet all eligibility criteria as outlined in the study...
ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence after Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection with and without Axillary Reverse Mapping

Principal Investigator:

Bret Taback, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT03927027

Population:

Adult

Phase:

III

The purpose of this study is to compare usual lymph node surgery to an added procedure during the surgery to help surgeons see the lymph node system better. During usual surgery, the lymph node system may be disrupted, which can cause swelling in the arm. This research study will use a new lymph node surgery technique to look at how fluid drains through the lymph node system in your upper arm. This new procedure could reduce the chance of developing arm swelling. But, it could also cause side effects. There will be about 516 people taking part in this study. This study will help the study...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages